Tip: Alleen in het Nederlands zoeken. Je kunt je zoektaal instellen in Voorkeuren
We highlight the progress, successes, and remaining challenges toward development of HSC gene therapies and discuss lessons they provide for development of ...
Histologically LuC can be divided into four groups: adenocarcinoma, squamous ... Beuzard, P. Leboulch, J.-A. Ribeil, J.-B. Arlet, F. Coté, G. Courtois ...
In this study, we explored the possibility of using aminoglycoside antibiotics to induce the production of a full-length functional p53 protein from a gene ...
De dag wordt afgesloten met de prijsuitreiking door de Schepen van Sport. ... Luc Beuzard Lucien Taelman Pat Leysen Patrick ... marathon: Kennemerland marathon – ...
17 mrt 2020 · Current results of lentiglobin gene therapy in patients with severe sickle cell disease treated under a refined protocol in the phase 1 Hgb-206 study
Invitrogen Anti-Ly-6A/E (Sca-1) Monoclonal (D7), eBioscience™, Catalog # 12-5981-82. Tested in Flow Cytometry (Flow) applications. This antibody reacts with ...
Bevat niet: jogging | Resultaten tonen met:jogging
Here we report a tumor-suppressive mode of action for growth-differentiation factor 11 (GDF11) and an unusual mechanism of its inactivation in TNBC.
Bevat niet: jogging | Resultaten tonen met:jogging
A, schematics of NEK2 promoter-luciferase (luc) reporters and associated luciferase activities. ... Beuzard, M. Marty, J.L. Misset, A. Janin, H. de Thé.
A method is described for regulating gene expression related to iron metabolism to ameliorate diseases that include sickle cell disease, cancers, ...
31 dec 2018 · We developed TALENs targeting the homologous HBG promoters to de-repress fetal hemoglobin. Transfection of human CD34+ cells with TALEN mRNA ...